Company Performance - Sunrun's stock increased by 1.2% to $20.28, outperforming the S&P 500's gain of 0.69% for the day [1] - Over the past month, Sunrun's stock has risen by 6.82%, which is lower than the Oils-Energy sector's increase of 14.14% and better than the S&P 500's decline of 1% [1] Earnings Expectations - Sunrun is expected to report earnings of -$0.08 per share on February 26, 2026, indicating a year-over-year decline of 105.67% [2] - Revenue is anticipated to reach $656.91 million, reflecting a 26.7% increase compared to the same quarter last year [2] Full Year Estimates - For the full year, analysts project earnings of $1.32 per share and revenue of $2.43 billion, representing changes of -0.75% and +19.22% respectively from the previous year [3] - Recent adjustments to analyst estimates for Sunrun may indicate shifting business dynamics, with positive revisions suggesting a favorable business outlook [3] Valuation Metrics - Sunrun currently has a Forward P/E ratio of 55.03, which is significantly higher than the industry average Forward P/E of 19.42 [5] - The Zacks Consensus EPS estimate has remained unchanged over the past month, and Sunrun holds a Zacks Rank of 2 (Buy) [5] Industry Context - The solar industry, part of the Oils-Energy sector, has a Zacks Industry Rank of 80, placing it in the top 33% of over 250 industries [6] - Strong individual industry groups, as measured by the Zacks Industry Rank, tend to outperform weaker groups by a factor of 2 to 1 [6]

Company Performance - Broadwind Energy, Inc. (BWEN) closed at $2.41, reflecting a -1.23% change from the previous day, underperforming the S&P 500's daily gain of 0.69% [1] - Over the past month, the company's shares have decreased by 27.16%, contrasting with the Industrial Products sector's gain of 9.59% and the S&P 500's loss of 1% [1] Upcoming Financial Results - Broadwind Energy, Inc. is set to announce its earnings on March 11, 2026, with projected earnings per share (EPS) of -$0.05, indicating a 25% decrease from the same quarter last year [2] - Revenue is expected to be $36.97 million, representing a 10.15% increase compared to the year-ago quarter [2] Full Year Projections - For the full year, Zacks Consensus Estimates project earnings of $0.21 per share and revenue of $157.52 million, reflecting changes of +320% and +10.05% respectively from the prior year [3] - Recent changes to analyst estimates for Broadwind Energy, Inc. are noted to reflect evolving short-term business trends, with positive revisions seen as a favorable sign for the business outlook [3] Zacks Rank and Industry Performance - Broadwind Energy, Inc. currently holds a Zacks Rank of 4 (Sell), with the Zacks Consensus EPS estimate having decreased by 263.64% over the past month [5] - The Manufacturing - General Industrial industry, part of the Industrial Products sector, has a Zacks Industry Rank of 67, placing it in the top 28% of over 250 industries [6]

Company Performance - Tilray Brands, Inc. (TLRY) closed at $7.75, reflecting a -1.77% change from the previous day, underperforming the S&P 500's gain of 0.69% [1] - Over the past month, shares of Tilray have decreased by 13.58%, while the Medical sector gained 0.77% and the S&P 500 lost 1% [1] Upcoming Earnings - The upcoming earnings release is anticipated, with an expected EPS of -$0.14, indicating an 86% growth compared to the same quarter last year [2] - Revenue is projected at $205.93 million, reflecting a 10.85% increase from the equivalent quarter last year [2] Annual Forecast - For the entire year, the Zacks Consensus Estimates forecast an EPS of -$0.56 and revenue of $871.99 million, indicating changes of -660% and +6.17% respectively compared to the previous year [3] Analyst Estimates - Recent modifications to analyst estimates for Tilray reflect shifting short-term business dynamics, with positive revisions indicating optimism about the business outlook [4] - The Zacks Rank system, which assesses estimate changes, currently ranks Tilray Brands, Inc. at 3 (Hold) [6] Industry Context - The Medical - Products industry, part of the Medical sector, has a Zacks Industry Rank of 148, placing it in the bottom 40% of over 250 industries [7] - Research indicates that top-rated industries outperform the bottom half by a factor of 2 to 1 [7]

Company Performance - Recursion Pharmaceuticals (RXRX) closed at $3.42, reflecting an -8.06% change from the previous day, underperforming the S&P 500 which gained 0.69% [1] - Prior to the latest trading session, RXRX shares had decreased by 25%, lagging behind the Medical sector's gain of 0.77% and the S&P 500's loss of 1% [1] Upcoming Financial Results - Recursion Pharmaceuticals is set to announce its earnings on February 25, 2026, with an expected EPS of -$0.28, indicating a 47.17% growth compared to the same quarter last year [2] - Revenue is projected to be $25.5 million, representing a significant 460.44% increase compared to the year-ago quarter [2] Full-Year Estimates - The Zacks Consensus Estimates for RXRX indicate expected earnings of -$1.59 per share and revenue of $64.62 million, reflecting year-over-year changes of +5.92% and +9.83%, respectively [3] - Recent modifications to analyst estimates for Recursion Pharmaceuticals suggest positive near-term business trends, with positive revisions seen as a favorable sign for the business outlook [3] Zacks Rank and Industry Performance - Recursion Pharmaceuticals currently holds a Zacks Rank of 2 (Buy), with the Zacks Consensus EPS estimate remaining unchanged over the past month [5] - The Medical - Biomedical and Genetics industry, part of the Medical sector, has a Zacks Industry Rank of 87, placing it in the top 36% of over 250 industries, indicating strong performance potential [6]

Core Viewpoint - Noble Corporation PLC (NE) shows a significant improvement in earnings outlook, making it an attractive investment option as analysts continue to raise earnings estimates for the company [1][2]. Earnings Estimate Revisions - The upward trend in earnings estimate revisions indicates growing analyst optimism regarding Noble Corporation's earnings prospects, which is expected to positively influence its stock price [2]. - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has a strong track record, with Zacks 1 Ranked stocks averaging a +25% annual return since 2008 [3]. - Consensus earnings estimates for the next quarter and the full year have increased significantly, reflecting strong agreement among analysts [3]. Current-Quarter Estimate - For the current quarter, Noble Corporation is expected to earn $0.17 per share, representing a year-over-year decline of -34.6% [5]. - Over the past 30 days, the Zacks Consensus Estimate for the company has risen by 25.93%, with one estimate moving higher and no negative revisions [5]. Current-Year Estimate - The full-year earnings estimate stands at $1.16 per share, indicating a year-over-year increase of +73.1% [6]. - The current year's revisions trend is promising, with one estimate moving higher and no negative revisions, leading to an 11.59% increase in the consensus estimate [6][7]. Zacks Rank - Noble Corporation currently holds a Zacks Rank 2 (Buy), indicating favorable estimate revisions that can help investors make informed decisions [8]. - Research shows that stocks with Zacks Rank 1 (Strong Buy) and 2 (Buy) tend to significantly outperform the S&P 500 [8]. Bottom Line - Strong estimate revisions have led to a 33.7% increase in Noble Corporation's stock over the past four weeks, suggesting potential for further upside, making it a candidate for portfolio addition [9].

Core Viewpoint - ONEOK Inc. (OKE) is set to release its fourth-quarter 2025 results on February 23, with an earnings surprise of 2.05% in the previous quarter [1] Factors Impacting Q4 Performance - The fourth-quarter earnings are expected to benefit from increased industrial demand from data centers, liquefied natural gas, and ammonia facilities [2] - Strong fee-based contracts, which account for over 90% of revenues, are anticipated to positively impact the bottom line [2] - Increased well completions in the Rocky Mountain and Mid-Continent regions are likely to have contributed to higher earnings and boosted natural gas gathering and processing volumes [3] Strategic Acquisitions - ONEOK has increased its stake in BridgeTex Pipeline Company, LLC, to 60% and acquired the remaining interest in Delaware G&P LLC, which is expected to yield significant cost savings and synergies, enhancing profitability [4] - However, higher interest expenses may have offset some of the gains in the upcoming quarter [4] Q4 Expectations - The Zacks Consensus Estimate for earnings is $1.50 per share, reflecting a year-over-year decrease of 4.5% [5] - Revenue is estimated at $9.49 billion, indicating a year-over-year increase of 35.6% [5] - Raw feed throughput is expected to be 1,650.68 thousand barrels of natural gas liquid per day, suggesting a 26.4% year-over-year growth [5] Natural Gas Processing Volumes - The Zacks Consensus Estimate for natural gas processing volumes is pegged at 5,825.78 million cubic feet of gas per day, implying a slight dip of 0.4% from the previous quarter [6] Earnings Prediction Model - The earnings prediction model does not indicate a conclusive earnings beat for ONEOK, with an Earnings ESP of -1.45% and a Zacks Rank of 4 (Sell) [7][8]

Core Viewpoint - Novanta (NOVT) is positioned well to potentially beat earnings estimates in its upcoming quarterly report, supported by a strong history of exceeding expectations [1]. Group 1: Earnings Performance - Novanta has a solid track record of surpassing earnings estimates, particularly in the last two quarters, with an average surprise of 5.06% [2]. - In the last reported quarter, Novanta achieved earnings of $0.87 per share, exceeding the Zacks Consensus Estimate of $0.81 per share, resulting in a surprise of 7.41% [3]. - For the previous quarter, the company was expected to report earnings of $0.74 per share but delivered $0.76 per share, yielding a surprise of 2.70% [3]. Group 2: Earnings Estimates and Predictions - Estimates for Novanta have been trending upward, aided by its history of earnings surprises, and the stock currently has a positive Zacks Earnings ESP of +1.14%, indicating bullish sentiment among analysts [6][9]. - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) suggests a high likelihood of another earnings beat, with historical data indicating that nearly 70% of stocks with this combination exceed consensus estimates [7][9]. Group 3: Earnings ESP Explanation - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions, which may provide more accurate predictions [8]. - A negative Earnings ESP can diminish the predictive power of the metric, but it does not necessarily indicate an earnings miss [10].

Core Viewpoint - Investors in the Medical - Instruments sector should consider SONOVA HOLDING (SONVY) and Idexx Laboratories (IDXX) for potential value opportunities [1] Group 1: Zacks Rank and Earnings Outlook - SONOVA HOLDING has a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, while Idexx Laboratories has a Zacks Rank of 3 (Hold) [3] - The Zacks Rank system favors stocks with positive revisions to earnings estimates, suggesting that SONVY has an improving earnings outlook [3] Group 2: Valuation Metrics - SONVY has a forward P/E ratio of 20.72, significantly lower than IDXX's forward P/E of 43.44, indicating that SONVY may be undervalued [5] - The PEG ratio for SONVY is 3.14, while IDXX has a PEG ratio of 3.84, suggesting that SONVY offers better value when considering expected earnings growth [5] - SONVY's P/B ratio is 4.94 compared to IDXX's P/B of 31.37, further indicating that SONVY is more favorably valued [6] - Based on these valuation metrics, SONVY holds a Value grade of B, while IDXX has a Value grade of D, reinforcing SONVY as the superior value option [6]

Core Viewpoint - The comparison between DocuSign (DOCU) and Adyen N.V. Unsponsored ADR (ADYEY) indicates that DOCU currently presents a better value opportunity for investors based on various financial metrics and rankings [1][3][7]. Valuation Metrics - DOCU has a forward P/E ratio of 10.61, significantly lower than ADYEY's forward P/E of 25.19, suggesting that DOCU may be undervalued relative to its earnings potential [5]. - The PEG ratio for DOCU is 0.74, indicating a favorable valuation when considering expected earnings growth, while ADYEY's PEG ratio stands at 1.49, suggesting it may be overvalued in this context [5]. - DOCU's P/B ratio is 4.48, compared to ADYEY's P/B of 6.97, further supporting the notion that DOCU is a more attractive investment based on its market value relative to book value [6]. Zacks Rank and Earnings Outlook - DOCU holds a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, while ADYEY has a Zacks Rank of 4 (Sell), suggesting a weaker earnings forecast [3][7]. - The improving earnings outlook for DOCU enhances its attractiveness as a value investment compared to ADYEY [7]. Value Grades - Based on the analysis of various financial metrics, DOCU has been assigned a Value grade of B, while ADYEY has a Value grade of F, highlighting the disparity in their investment potential [6].

Core Viewpoint - Holcim Ltd Unsponsored ADR (HCMLY) is currently viewed as a better value opportunity compared to Installed Building Products (IBP) based on various financial metrics and analyst outlooks [1][3]. Valuation Metrics - HCMLY has a forward P/E ratio of 21.16, while IBP has a higher forward P/E of 29.29, indicating that HCMLY may be undervalued relative to IBP [5]. - The PEG ratio for HCMLY is 2.00, compared to IBP's PEG ratio of 7.04, suggesting that HCMLY offers better value when considering expected earnings growth [5]. - HCMLY's P/B ratio stands at 2.87, significantly lower than IBP's P/B ratio of 12.85, further supporting the notion that HCMLY is more attractively valued [6]. Analyst Outlook - HCMLY has a Zacks Rank of 2 (Buy), indicating a positive earnings estimate revision activity, while IBP has a Zacks Rank of 4 (Sell), reflecting a less favorable analyst outlook [3][7]. - The stronger estimate revision activity for HCMLY suggests a more optimistic future performance compared to IBP, making it a more appealing choice for value investors [7].